KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial.

Scott K Heysell, Stellah G Mpagama, Edwin Nuwagira, Bibie Said, Mark Conaway, Megan Null, Tania A Thomas, David R Boulware, Eva Otoupalova, Rinah Arinaitwe, Rhina Mushagara, Louisa Edwards, Peter Buzaare, Athumani M Ngoma, Davis Muganzi, Geofrey Gidoi, Samuel Jjunju, Antony Gulinja, Arestaricky G Rimoy, Fredrick C Mwita, Jeremiah Kidola, Oscar Atwiine, David Ocaaki, Dalton K Munyambalu, Jie Liu, Lucas Ampaire, Buliga Mujaga, Prakruti Rao, Alphonce Liyoyo, Margaretha Sariko, Conrad Muzoora, Christopher C Moore

Lancet Infect Dis 26(6) 601-613

PMID41619753
PMCIDPMC13040453
DOI10.1016/S1473-3099(25)00747-9
发表日期2026-01-31
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1::非 KM 图;Figure 2::非 KM 图;Figure 3::非 KM 图;Figure 4::森林图/亚组分析图。
摘要

摘要

BACKGROUND: People living with HIV and hospitalised with sepsis in Africa are at risk of death due to tuberculosis but diagnostics for tuberculosis might be delayed or inaccessible for people presenting for critical care. We aimed to compare the effects of immediate empirical and high-dose antituberculosis therapy on 28-day mortality in adult people living with HIV with sepsis in east Africa. METHODS: ATLAS was a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial conducted at four hospitals in Tanzania and Uganda. Participants were aged 18 years or older, living with HIV, and had been admitted to hospital with sepsis with two or more modified quick Sequential Organ Failure Assessment score criteria. Exclusion criteria were active tuberculosis or receipt of antituberculosis therapy within 6 months of hospitalisation, pregnancy or lactation, allergies to antituberculosis therapy, another investigational drug within the past month, chronic liver disease, heavy alcohol use, positive serum cryptococcal antigen, or anticipated significant drug-drug interaction with rifampicin. A computer-generated permuted-block algorithm with allocation concealment and random block sizes of four and eight randomly assigned participants (1:1) to receive either immediate or diagnosis-dependent antituberculosis therapy, and (1:1) to receive either high-dose or conventional WHO-recommended weight-based dose antituberculosis therapy. Allocation was stratified by country and the presence of altered mental status at the time of randomisation. Participants randomly assigned to conventional-dose antituberculosis therapy received fixed-dose combination tablets of rifampicin approximately 10 mg/kg, isoniazid approximately 5 mg/kg, pyrazinamide, and ethambutol, plus pyridoxine 50 mg orally. Participants randomly assigned to receive high-dose antituberculosis therapy received rifampicin approximately 30 mg/kg and isoniazid approximately 7·5 mg/kg as a combination of single formulation tablets and fixed-dose combination tablets that included WHO-recommended weight-based doses of pyrazinamide and ethambutol, plus pyridoxine. Participants continued immediate antituberculosis therapy for 28 days. All medications were administered daily. Participants in the diagnosis-dependent antituberculosis therapy groups received treatment based on a clinical or microbiological diagnosis of tuberculosis. All participants received 2 g intravenous ceftriaxone daily for 7 days. The primary endpoint was 28-day mortality analysed in the modified intention-to-treat population and in the subgroup with later confirmed tuberculosis. We defined the survival time for each participant as the time from randomisation until death, discharged (alive) by day 28, or censored (alive) at day 28. We graded adverse events according to recommendations from the National Institutes of Health Division of AIDS. This study was registered with ClinicalTrials.gov, NCT04618198, and is completed. FINDINGS: Between Jan 5, 2022, and Dec 9, 2024, 707 people were screened for eligibility and 437 were randomly assigned (110 to immediate conventional-dose, 112 to immediate high-dose, 107 to diagnosis-dependent conventional-dose, and 108 to diagnosis-dependent high-dose antituberculosis therapy). 395 patients (226 [57%] of whom were female and 169 [43%] were male; all participants were Black) received study intervention and were analysed for the primary outcome of 28-day mortality. We confirmed tuberculosis in 204 (52%) patients. There was no evidence of differences in 28-day mortality in immediate antituberculosis therapy groups (50 deaths [25%] in 198 patients) compared with diagnosis-dependent groups (50 deaths [25%] in 197 patients; adjusted hazard ratio [aHR] 0·99 [95% CI 0·67-1·46]; p=0·95), or in high-dose antituberculosis therapy groups (51 deaths [26%] in 199 patients) compared with conventional-dose groups (49 deaths [25%] in 196 patients; aHR 1·07 [0·72-1·59]; p=0·73). In patients with microbiologically confirmed tuberculosis, the 28-day mortality relative to the diagnosis-dependent conventional-dose group (18 deaths [34%] in 53 patients) was lower for the immediate conventional-dose group (six deaths [12%] in 51 participants; aHR 0·32 [95% CI 0·13-0·82]; p=0·015); for the diagnosis-dependent high-dose group (11 deaths [20%] in 56 patients) was 0·51 (0·24-1·08; p=0·079); and for the immediate high-dose group (11 deaths [26%] in 43 patients) was 0·63 (0·29-1·36; p=0·24). No significant differences in adverse events occurred between treatment groups but numerically more events of drug-induced liver injury occurred in the immediate high-dose group compared with any other group. INTERPRETATION: Among all participants with HIV-related sepsis, 28-day mortality was not significantly reduced with immediate or high-dose antituberculosis therapy. In the subgroup with later confirmed tuberculosis, immediate conventional-dose antituberculosis therapy significantly reduced 28-day mortality, suggesting, as in other forms of bacterial sepsis, that hours to active treatment might determine survival. FUNDING: US National Institutes of Health.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1:Trial profile *One individual had a positive cryptococcal antigen result and was already receiving antituberculosis therapy. †One participant had both elevated serum creatinine and liver enzymes.
非 KM Figure
Figure 2:28-day mortality (A) 28-day mortality in the immediate versus the diagnosis-dependent antituberculosis therapy groups (both conventional-dose and high-dose). (B) 28–day mortality in the conventional-dose versus high-dose antituberculosis therapy groups (both immediate and dose-dependent). (C) 28-day mortality in the immediate conventional-dose versus the immediate high-dose antituberculosis therapy groups. (D) 28-day mortality in the diagnosis-dependent conventional-dose versus the diagnosis-dependent high-dose antituberculosis therapy groups. Percentages for each group are the day 28 survival proportions, estimated from the Kaplan–Meier curves.
非 KM Figure
Figure 3:28-day mortality in participants with and without later confirmed tuberculosis (A) 28-day mortality in participants with confirmed tuberculosis. (B) 28-day mortality in participants without confirmed tuberculosis. (C) 28-day mortality in participants with confirmed tuberculosis bloodstream infection. (D) 28-day mortality in participants with other non-tuberculosis bloodstream infection. DC=diagnosis-dependent conventional-dose antituberculosis therapy (standard of care). Percentages for each group are the day 28 mortality proportions, estimated from the Kaplan–Meier curves. DH=diagnosis-dependent high-dose antituberculosis therapy. IC=immediate conventional-dose antituberculosis therapy. IH=immediate high-dose antituberculosis therapy.
非 KM Figure
Figure 4:Forest plots of risk of death at 28 days for prespecified subgroups relative to the standard of care aHRs and 95% CI were adjusted for country and altered mental status compared with the standard of care group (DC) to IC, IH, and DH. aHR=adjusted hazard ratio. ART=antiretroviral therapy. DC=diagnosis-dependent conventional-dose antituberculosis therapy (standard of care). DH=diagnosis-dependent high-dose antituberculosis therapy. IC=immediate conventional-dose antituberculosis therapy. IH=immediate high-dose antituberculosis therapy. UVA=Universal Vital Assessment.
非 KM Figure